These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1789811)

  • 1. Lipid-lowering drugs: focus on HMG-CoA reductase inhibitors. Introduction.
    Thompson GR
    Atherosclerosis; 1991 Dec; 91 Suppl():S1-2. PubMed ID: 1789811
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Jolain B; Pettitt D
    Clin Ther; 1995; 17(3):572-80. PubMed ID: 7585861
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
    Ginsberg HN
    Clin Cardiol; 1995 Jun; 18(6):307-15. PubMed ID: 7664504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statins (HMG-CoA reductase inhibitors)].
    Gotoda T
    Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hyperlipidemia in the elderly].
    Kawano M
    Nihon Rinsho; 2002 May; 60(5):1017-23. PubMed ID: 12029980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
    Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
    Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
    Pedersen TR
    J Hypertens Suppl; 1996 Dec; 14(5):S195-200. PubMed ID: 9120679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins: effects beyond cholesterol lowering.
    Massy ZA; Guijarro C
    Nephrol Dial Transplant; 2001 Sep; 16(9):1738-41. PubMed ID: 11522848
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
    Tachibana-Iimori R; Tabara Y; Kusuhara H; Kohara K; Kawamoto R; Nakura J; Tokunaga K; Kondo I; Sugiyama Y; Miki T
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):375-80. PubMed ID: 15548849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of lipid lowering drugs in general practice: article illustrates major problem.
    Wang TW; Livingstone CA; Ferns GA
    BMJ; 2003 Jul; 327(7405):50-1; author reply 51. PubMed ID: 12842961
    [No Abstract]   [Full Text] [Related]  

  • 13. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future treatment of hyperlipidemia: the role of statins.
    Farnier M; Davignon J
    Am J Cardiol; 1998 Aug; 82(4B):3J-10J. PubMed ID: 9737640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology and therapeutics of lipid-lowering drugs.
    Hunninghake DB
    Am Pharm; 1987 Nov; NS27(11):S18-25. PubMed ID: 3425537
    [No Abstract]   [Full Text] [Related]  

  • 16. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatment.
    Shviro I; Leitersdorf E
    Cardiology; 1996; 87(6):469-75. PubMed ID: 8904672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-atherogenic drugs].
    Kanaki T; Saito Y
    Nihon Rinsho; 1998 Oct; 56(10):2635-9. PubMed ID: 9796331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
    Jones PH
    Drugs; 2000 May; 59(5):1127-35. PubMed ID: 10852644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.